Dark
Light
Today: November 29, 2025
March 1, 2024
1 min read

Boston’s February VC Funding Roundup: Which Startups Scored Big?

TLDR:

In this article, researchers have discovered a potential new treatment for Alzheimer’s disease involving a drug called Nilotinib. The drug has shown promise in mice studies by reducing the build-up of toxic proteins in the brain. Human trials are set to begin soon to further investigate the effectiveness of Nilotinib in treating Alzheimer’s.

A team of researchers have found that the drug Nilotinib has the potential to be a breakthrough treatment for Alzheimer’s disease. In studies conducted on mice, Nilotinib was found to reduce the accumulation of toxic proteins in the brain that are associated with Alzheimer’s.

The researchers are hopeful that Nilotinib could have similar effects in humans and are planning to conduct clinical trials to test its effectiveness in treating Alzheimer’s disease. If successful, Nilotinib could be a game-changer in the field of Alzheimer’s research and provide hope for millions of people affected by the disease.

Previous Story

Launch of Entourage: €277M Fund for European SaaS Founders

Next Story

Top Houston news: 2 VCs debut, RBPC participants revealed

Latest from Blog

VCFA Group Closes $1225M Venture Partners VII Fund

TLDR: VCFA Group closed VCFA Venture Partners VII fund with $122.5 million in commitments Transition marks continuation of VCFA’s pioneering legacy in the secondary private equity space VCFA Group, a pioneer in

Top AI Trends and Startups Shaping 2025 and Beyond

“`html TLDR: Israel is excelling in applicative and vertical AI, focusing on practical solutions in cybersecurity, healthcare, and defense rather than competing with tech giants in foundational AI models. Five key AI
Go toTop